Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Application of electrical impedance myography to capture disease progression in inclusion body myositis
Neuromuscular and Clinical Neurophysiology (EMG)
P16 - Poster Session 16 (5:30 PM-6:30 PM)
1-005

To examine if electrical impedance myography (EIM) can capture disease progression in inclusion body myositis (IBM).


Electrical impedance myography (EIM) has shown promise as a biomarker in several neuromuscular disorders. We have previously noted significant lower EIM 50 kHz phase value (EIM50) from averaged 6 muscles in IBM patients compared to healthy controls. In this ongoing study, we examined changes in EIM50, along with some clinical outcome measures, in IBM patients over 6 months.


Longitudinal, observational study. We have assessed EIM50 from deltoid, biceps, forearm flexors, quadriceps, medial gastrocnemius, and tibialis anterior, along with IBM-functional rating scale (IBM-FRS) score, and manual muscle strength testing (MMT: total score of 160) at baseline and 6-month.

To date, we have recruited 5 participants (4 men, 1 woman, age 67.8 ± 4.7 years) with clinically defined IBM with varying degrees of disease severity (IBM-FRS score ranging between 17-36). EIM50 values from averaged six-muscles decreased from 5.81 ± 1.66 at baseline to 5.43 ± 1.19 at 6-month. IBM-FRS score changed from 28.2 ± 7.8 to 26.8 ± 7.6, and total MMT changed from 137 ± 13.9 to 135.6 ± 15.4. Changes from mean baseline values in 6-muscle averaged EIM was 7%, compared to 5% change in IBM-FRS, and 1% change in total MMT. EIM changes were more prominent in patients with IBM-FRS score ≥ 26 (3 out of 5). Averaged 6-muscle EIM50 value changed from 6.43 ± 2 to 5.71 ± 1.6. Similar decrement was noted in averaged upper and lower extremity muscles among these patients; 5.99 ± 1.2 to 5.29 ± 1.2, and 6.87 ± 3 to 6.13 ± 2.2 respectively.


EIM may prove valuable to assess disease progression in IBM. However, the sample size is too small to make any definitive conclusion. A larger-scale study with longer follow up is warranted.


Authors/Disclosures
Bhaskar Roy, MD, FÂ鶹´«Ã½Ó³»­ (Yale University)
PRESENTER 		Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Roy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Roy has or had stock in Cabaletta bio. .Dr. Roy has or had stock in Pfizer.Dr. Roy has or had stock in CAVA. The institution of Dr. Roy has received research support from Abcuro Pharmaceuticals. The institution of Dr. Roy has received research support from Immunovant. The institution of Dr. Roy has received research support from argenx.
Seward B. Rutkove, MD, FÂ鶹´«Ã½Ó³»­ Dr. Rutkove has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Myolex, Inc. Dr. Rutkove has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neuorlogy . The institution of Dr. Rutkove has received research support from NIH. The institution of Dr. Rutkove has received research support from NASA. The institution of Dr. Rutkove has received research support from Blavatnik Family Foundation. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with NIH.
No disclosure on file
Richard J. Nowak, MD (Yale University School of Medicine) Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Nowak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio . Dr. Nowak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cour Pharma. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janseen . The institution of Dr. Nowak has received research support from UCB. The institution of Dr. Nowak has received research support from Alexion . The institution of Dr. Nowak has received research support from Janseen. The institution of Dr. Nowak has received research support from Immunovant . The institution of Dr. Nowak has received research support from argenx. The institution of Dr. Nowak has received research support from Amgen. Dr. Nowak has a non-compensated relationship as a Member of the Board of Directors with Myasthenia Gravis Foundation of America (MGFA) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.